newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra
Health

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Ivabradine Tablets, 5 mg and 7.5 mg

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Ivabradine Tablets

12th November 2024, Bengaluru: Alembic Pharmaceuticals Limited (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ivabradine Tablets, 5 mg and 7.5 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Corlanor Tablets, 5 mg and 7.5 mg, of Amgen Inc. (Amgen).

Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. Refer label for a detailed indication.

Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US$ 145.3 million for twelve months ending September 2024 according to IQVIA.

Alembic has a cumulative total of 218 ANDA approvals (192 final approvals and 26 tentative approvals) from USFDA.

Related posts

In-Med announces NeuroShield CT, an AI Tool to help reduce mortality rates in neurotrauma

Newsmantra

MAHE signs MOU with SKAN and Happiest Health for academics, research and consultancy

Newsmantra

Sitaram Jaipuria Foundation to honour lifesavers at the second Medical & Healthcare Excellence Awards

Newsmantra

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More